Skip to content

Company · founded 2002

ConfometRx (United States)

Santa Clara, United States · confometrx.com

Manage this page

Citations, last 5 years: 126
Works, last 5 years: 875
h-index: 40
Scientists listed: 1
Grants since 2016: 11

Grants received

2023–2024 · research · R43

Discovery of GPR171 small molecule ligands for the treatment of chronic pain

Bingfa Sun · ConfometRx (United States) · funded by National Institutes of Health

$298.3kReceptor Mechanisms and Signaling

2023–2024 · research · R43

Discovery of GPR75 small molecule ligands for the treatment of obesity

Bingfa Sun · ConfometRx (United States) · funded by National Institutes of Health

$303.4kDiabetes Treatment and Management

2017–2021 · research · R44

Structure-based discovery of dopamine D1 receptor selective small molecule ligands

Dan Feng · ConfometRx (United States) · funded by National Institutes of Health

$676.1kReceptor Mechanisms and Signaling

2017–2022 · research · R44

Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands

Victoria Ahn · ConfometRx (United States) · funded by National Institutes of Health

$659.2k

2017–2023 · research · R44

Structure-based discovery of dopamine D1 receptor selective small molecule ligands

Dan Feng · ConfometRx (United States) · funded by National Institutes of Health

$676.1kReceptor Mechanisms and Signaling

2017–2022 · research · R44

Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands

Victoria Ahn · ConfometRx (United States) · funded by National Institutes of Health

$764.5k

2017–2018 · research · R44

Structure-based discovery of dopamine D1 receptor selective small molecule ligands

Dan Feng · ConfometRx (United States) · funded by National Institutes of Health

$381.5kReceptor Mechanisms and Signaling

2017–2021 · research · R44

Structure-based discovery of dopamine D1 receptor selective small molecule ligands

Dan Feng · ConfometRx (United States) · funded by National Institutes of Health

$676.1kReceptor Mechanisms and Signaling

2017–2024 · research · R44

Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands

Victoria Ahn · ConfometRx (United States) · funded by National Institutes of Health

$738.1k

2017–2018 · research · R43

Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands

Victoria Ahn · ConfometRx (United States) · funded by National Institutes of Health

$193.7k

2017–2018 · research · R44

Structure-based discovery of dopamine D1 receptor selective small molecule ligands

Dan Feng · ConfometRx (United States) · funded by National Institutes of Health

$376.5kReceptor Mechanisms and Signaling